|Articles|June 1, 1996

June 1996
Volume 2
Issue 6

The Emerging Use of Economic Models in the Life-Cycle of Pharmaceutical Products

Author(s)Timothy R. Hylan, PhD, Carol Andrejasich, MBA, Jane C. Haley, MBA

Download PDF: The Emerging Use of Economic Models in the Life-Cycle of Pharmaceutical Products

Articles in this issue

about 30 years ago

Article

Consequences of Prior Authorization Programs -- A Case Example: DDAVP in Pediatric Nocturnal Enuresis

about 30 years ago

Article

Chest Pain

about 30 years ago

Article

The Corporatization of American Medicine: The Impact of Managed Care on the Doctor-Patient Relationship

about 30 years ago

Article

Correspondence regarding, "Diagnosis and Eradication of Helicobacter pylori in the Management of Peptic Ulcer Disease: A Decision Analysis Model"

about 30 years ago

Article

Correspondence regarding Computed Tomography Scans

about 30 years ago

Article

Outcome and Cost Analysis of Preterm Premature Rupture of Membranes in an Outpatient Setting

about 30 years ago

Article

An Alternative Framework for Evaluating the Efficiency of Managed Care

about 30 years ago

Article

Management of Dyspepsia: A Decision Analysis Model

about 30 years ago

Article

The Effectiveness of an Influenza Vaccination Program in an HMO Setting

about 30 years ago

Article

Primary Care Physicians' Attitudes Toward Capitated Care: A Potential Quality of Care Measure

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

The Emerging Use of Economic Models in the Life-Cycle of Pharmaceutical Products

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

FAQs: FDA Lawsuit Challenges E-Cigarette Enforcement Policy, PMTA Guidance

Medicaid MFN Pricing Could Save $8.6 Billion

Active US Drug Shortages Rise for Third Straight Quarter

Cognitive Rehabilitation Improves Functional Outcomes in Long COVID Brain Fog

Adding Epcoritamab to R2 in R/R Follicular Lymphoma Meets Cost-Effectiveness Tests